Literature DB >> 1902193

Gamma interferon suppresses acute and chronic Trypanosoma cruzi infection in cyclosporin-treated mice.

R McCabe1, S Meagher, B Mullins.   

Abstract

To determine if exogenous gamma interferon is effective in immunosuppressed mice infected with Trypanosoma cruzi, recombinant murine gamma interferon was administered to cyclosporin-treated mice with either acute or chronic T. cruzi infection. Gamma interferon significantly decreased parasitemia and prevented death in acutely infected mice. Parasitemias and mortality of mice treated with both gamma interferon and cyclosporin were similar to those of immunocompetent controls. In chronically infected mice, cyclosporin treatment produced significantly more organ explant cultures positive for T. cruzi. Fewer positive cultures, particularly for spleen and heart, were obtained from cyclosporin-treated mice when they also received gamma interferon. Ketoconazole treatment of mice resulted in no positive cultures. Cyclosporin treatment did not prevent activation of peritoneal macrophages by parenteral gamma interferon, nor did it have a consistent effect on serum titers of alpha/beta or gamma interferon in response to a second challenge inoculum of T. cruzi. These data indicate that exogenous gamma interferon suppresses acute and chronic T. cruzi infection in cyclosporin-treated mice but that gamma interferon is not as effective as the relatively specific antimicrobial ketoconazole. Gamma interferon activates macrophages despite cyclosporin treatment, and its effects appear to be tissue specific.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902193      PMCID: PMC257895          DOI: 10.1128/iai.59.5.1633-1638.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Effects of intradermal gamma-interferon in cutaneous leishmaniasis.

Authors:  G Harms; K Zwingenberger; A K Chéhadé; S Talhari; P Racz; A Mouakeh; M Douba; L Näkel; R D Naiff; P G Kremsner
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

2.  Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy.

Authors:  C F Nathan; G Kaplan; W R Levis; A Nusrat; M D Witmer; S A Sherwin; C K Job; C R Horowitz; R M Steinman; Z A Cohn
Journal:  N Engl J Med       Date:  1986-07-03       Impact factor: 91.245

3.  Failure of ketoconazole to cure chronic murine Chagas' disease.

Authors:  R McCabe
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

4.  Effect of murine interferon gamma on murine toxoplasmosis.

Authors:  R E McCabe; B J Luft; J S Remington
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

5.  Prevention by gamma interferon of fatal infection with Listeria monocytogenes in mice treated with cyclosporin A.

Authors:  A Nakane; T Minagawa; I Yasuda; C Yu; K Kato
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

6.  In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections.

Authors:  S G Reed
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

7.  Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism.

Authors:  R E McCabe; J S Remington; F G Araujo
Journal:  J Infect Dis       Date:  1984-10       Impact factor: 5.226

8.  Trypanosoma cruzi: explant organ cultures from mice with chronic Chagas' disease.

Authors:  R E McCabe; S Meagher; B Mullins
Journal:  Exp Parasitol       Date:  1989-05       Impact factor: 2.011

9.  Inhibition of cytokine production by cyclosporin A and transforming growth factor beta.

Authors:  T Espevik; I S Figari; M R Shalaby; G A Lackides; G D Lewis; H M Shepard; M A Palladino
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

10.  Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A.

Authors:  A Granelli-Piperno; L Andrus; R M Steinman
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

View more
  6 in total

1.  Gastric invasion by Trypanosoma cruzi and induction of protective mucosal immune responses.

Authors:  D F Hoft; P L Farrar; K Kratz-Owens; D Shaffer
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

2.  Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi.

Authors:  D F Hoft; A R Schnapp; C S Eickhoff; S T Roodman
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

3.  Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  Vaccine       Date:  2012-10-15       Impact factor: 3.641

4.  A recombinant protein based on the Trypanosoma cruzi metacyclic trypomastigote 82-kilodalton antigen that induces and effective immune response to acute infection.

Authors:  R Santori F; G S Paranhos-Bacalla; J Franco DA Silveira; L M Yamauchi; J E Araya; N Yoshida
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

5.  A DNA vaccine encoding for TcSSP4 induces protection against acute and chronic infection in experimental Chagas disease.

Authors:  Minerva Arce-Fonseca; Angel Ramos-Ligonio; Aracely López-Monteón; Berenice Salgado-Jiménez; Patricia Talamás-Rohana; José Luis Rosales-Encina
Journal:  Int J Biol Sci       Date:  2011-10-25       Impact factor: 6.580

6.  TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.